VERTEPORFIN for Photodynamic therapy: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 13 adverse event reports in the FDA FAERS database where VERTEPORFIN was used for Photodynamic therapy.
Most Reported Side Effects for VERTEPORFIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Visual acuity reduced | 173 | 23.0% | 0 | 3 |
| Off label use | 129 | 17.1% | 1 | 1 |
| Polypoidal choroidal vasculopathy | 128 | 17.0% | 0 | 5 |
| Disease progression | 115 | 15.3% | 0 | 3 |
| Age-related macular degeneration | 90 | 12.0% | 0 | 3 |
| Retinal haemorrhage | 70 | 9.3% | 0 | 8 |
| Product use in unapproved indication | 57 | 7.6% | 1 | 1 |
| Choroidal neovascularisation | 47 | 6.2% | 0 | 3 |
| Retinal detachment | 42 | 5.6% | 0 | 2 |
| Subretinal fluid | 42 | 5.6% | 0 | 0 |
| Detachment of retinal pigment epithelium | 36 | 4.8% | 0 | 0 |
| Macular degeneration | 33 | 4.4% | 0 | 2 |
| Cystoid macular oedema | 26 | 3.5% | 0 | 0 |
| Drug ineffective | 23 | 3.1% | 0 | 0 |
| Product use issue | 21 | 2.8% | 0 | 0 |
Other Indications for VERTEPORFIN
Age-related macular degeneration (256)
Polypoidal choroidal vasculopathy (210)
Chorioretinopathy (107)
Product used for unknown indication (82)
Choroidal neovascularisation (42)
Macular degeneration (41)
Product use in unapproved indication (40)
Choroidal haemangioma (29)
Neovascular age-related macular degeneration (16)
Detachment of retinal pigment epithelium (8)